Clinical Trials
2
Active:1
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND1 Mutations
Phase 1
Recruiting
- Conditions
- Leber Hereditary Optic Neuropathy (LHON)
- Interventions
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Neurophth Therapeutics Inc
- Target Recruit Count
- 18
- Registration Number
- NCT05820152
- Locations
- 🇺🇸
University of Colorado- Dept of Ophthalmology, Aurora, Colorado, United States
🇨🇳The First Medical Center of the General Hospital of the Chinese People's Liberation Army, Beijing, Beijing, China
🇨🇳Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong, China
Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND4 Mutations
Phase 1
Active, not recruiting
- Conditions
- Leber Hereditary Optic Neuropathy (LHON)
- Interventions
- Drug: NR082 InjectionDevice: Injection needle
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Neurophth Therapeutics Inc
- Target Recruit Count
- 12
- Registration Number
- NCT05293626
- Locations
- 🇺🇸
Stanford Byers Eye Institute, Palo Alto, California, United States
🇺🇸University of Colorado Health Eye Center, Aurora, Colorado, United States
🇺🇸Wills Eye Hospital, Neuro Ophthalmology Department, Philadelphia, Pennsylvania, United States
News
No news found